<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680715</url>
  </required_header>
  <id_info>
    <org_study_id>2020/33</org_study_id>
    <nct_id>NCT04680715</nct_id>
  </id_info>
  <brief_title>Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer</brief_title>
  <acronym>RPOS+2</acronym>
  <official_title>Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study; open recruitment, multicentrique. The aim of this clinical research is to&#xD;
      evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM&#xD;
      device for localized breast cancers patients over 65 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>radiotherapy treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>early toxicities occuring until 6 months after performing per-operative radiotherapy</measure>
    <time_frame>up to 6 months</time_frame>
    <description>pourcentage of patient with toxicities of grade 3 and more (by CTCAE v5.0) related to per-operative radiotherapy and that occured until 6 months after performing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>global tolerance of per-operative radiotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <description>global safety (assessed by CTCAE V5.0) of per-operative radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local disease free survival at 5 years of per-operative radiotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To evaluate local disease free survival at 5 years of per-operative radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival at 5 years of per-operative radiotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To evaluate disease free survival at 5 years of per-operative radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life of patients</measure>
    <time_frame>up to 6 months</time_frame>
    <description>QLQ-C30 and QLQ BR-23 EORTC questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Localized Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Per-Operative Radiotherapy technique by Papillon +TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Per-Operative Radiotherapy technique by Papillon +TM</intervention_name>
    <description>20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer</description>
    <arm_group_label>Per-Operative Radiotherapy technique by Papillon +TM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with invasive ductal adenocarcinoma &lt;=2cm, evaluate on all radiological exams;&#xD;
&#xD;
          -  Women aged 65 years or older (patients 65 years of age in the year may be included);&#xD;
&#xD;
          -  Grade 1 or 2 unifocal adenocarcinoma, all index KI67, positive HR, negative HER2&#xD;
             status;&#xD;
&#xD;
          -  T0 or T1, N0 radio-clinic;&#xD;
&#xD;
          -  Operable patient with breast volume compatible with conservative surgery;&#xD;
&#xD;
          -  Patient with prior malignancy or other concurrent malignancies are eligible, including&#xD;
             bilateral breast cancer&#xD;
&#xD;
          -  Patients who have been made aware of the information sheet and have given their&#xD;
             written signed informed consent;&#xD;
&#xD;
          -  Patients benefitting from social health insurance coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 65 years (except if 65 years obtained during the year)&#xD;
&#xD;
          -  Patient with an exclusive in situ carcinoma&#xD;
&#xD;
          -  Patient with lymphatic invasion / peri-nerve involvement / vascular emboli&#xD;
&#xD;
          -  Patient with a lobular adenocarcinoma&#xD;
&#xD;
          -  Patient with metastatic disease&#xD;
&#xD;
          -  Multifocal tumor&#xD;
&#xD;
          -  Patient with grade 3 or N+ disease&#xD;
&#xD;
          -  N1 proved by ultrasound guided&#xD;
&#xD;
          -  patient unable to express her consent&#xD;
&#xD;
          -  Patient deprived placed under the authority of a tutor&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  Vulnerable patient: as defined in article L1121-5 à -8&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frédérique JACQUINOT</last_name>
    <phone>04 92 03 10 24</phone>
    <phone_ext>+33</phone_ext>
    <email>drci-promotion@nice.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pôle Santé République</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annie ITIE</last_name>
    </contact>
    <investigator>
      <last_name>Vivien FUNG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien CHAUVIERE</last_name>
      <phone>0492031365</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Marie-Eve FOUCHE-CHAND, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

